Cancer Neuroscience Training Program

摘要 光遗传学和单细胞基因组学等当代新技术表明， 神经元刺激成人和小儿神经胶质瘤的生长。相反，癌症和癌症治疗会改变 神经系统形式和功能（例如，癌症治疗相关的认知障碍，俗称 “chemobrain "或”chemofog”）。肿瘤和神经系统之间的双向对话定义了一个 一门新兴的科学学科，被称为“癌症神经科学”。布里格姆大学神经病学系 和妇女医院（BWH），以及哈佛医学院神经生物学系 (HMS)提出了一个综合性的，第一次在实物博士后培养计划在这个新的领域。该计划将 由临床科学家Tracy Batchelor博士共同领导。（BWH神经病学主席）和基础科学家Michael Greenberg博士（联合主任，哈佛脑科学倡议）。29名导师将从 丹娜-法伯/哈佛癌症中心和来自哈佛脑科学倡议。这将是一门基础科学 程序.博士候选人和/或医学博士学位将有资格，但不会有临床训练。 我们要求每年支持6名博士后研究员，任期2年。该计划将 促进这些受训人员的科学发展和专业发展。科学 发展，该计划将带来博士水平的基础科学家与技能，在神经发育， 电生理学，神经电路，光遗传学，脑代谢和神经化学的实验室， 从事原发性和转移性脑癌研究的临床/转化研究人员。用于实验室 研究，研究员将被教导，以确定重要的问题和方法，将推动该领域向前发展 并提供转化机会来影响癌症治疗。在专业发展方面，我们将 为受训人员提供（i）改善和加强其学术和科学交流的机会 （二）个人发展计划;（三）个人博士后指导委员会;（四）定制 学员有机会根据其职业目标获得辅导和教学经验。 项目主任和联合主任将与培训监督委员会和 外部咨询委员会。与Morehouse医学院和 马萨诸塞大学波士顿分校（纽约州最大的少数民族学生高等教育中心） 英格兰）将帮助确定如何招募代表性不足的少数民族参加该计划，并保持一个 为这些实习生创造良好的环境。衡量学员满意度的其他策略， 结果，并评估该计划的有效性将包括对受训人员的年度调查， 导师，以及退出和校友面试。以最先进的核心设施为形式的机构支助， 支持T32特定培训活动和EAB年度会议的技术平台和资金将 大大加强了培训计划。

Abstract Contemporary new technologies such as optogenetics and single cell genomics show that electrically active neurons stimulate growth of adult and pediatric gliomas. Conversely, cancers and cancer therapies alter nervous system form and function (e.g., cancer therapy-related cognitive impairment colloquially known as ‘‘chemobrain’’ or ‘‘chemofog”). The two-way dialogue between tumors and the nervous system defines an emerging new scientific discipline termed “Cancer Neuroscience”. The Department of Neurology at Brigham and Women’s Hospital (BWH), together with the Department of Neurobiology at Harvard Medical School (HMS), propose an integrative, first-in-kind postdoctoral training program in this new field. The Program will be co-led by a clinician scientist, Tracy Batchelor, M.D. (Chair of Neurology at BWH) and a basic scientist Michael Greenberg, Ph.D. (co-director, Harvard Brain Science Initiative). A faculty of 29 mentors will be drawn from the Dana-Farber/Harvard Cancer Center and from the Harvard Brain Science Initiative. This will be a basic science program. Candidates with Ph.D. and/or M.D. degrees will be eligible but there will be no clinical training. We request support for 6 postdoctoral fellows per year to serve 2-year appointments. The Program will foster both scientific development and professional development of these trainees. For Scientific Development, the Program will bring doctorate level basic scientists with skill sets in neural development, electrophysiology, neural circuitry, optogenetics, brain metabolism and neurochemistry into the laboratories of clinical/translational investigators working on primary and also metastatic cancers of the brain. For laboratory research, fellows will be taught to identify important questions and approaches that will move the field forward and provide translational opportunities to impact cancer treatment. For professional development, we will provide trainees with (i) opportunities to refine and enhance their grantsmanship and scientific communication skills; (ii) individual Development Plans; (iii) individual postdoctoral mentoring committees, and (iv) customized opportunities for trainees to acquire experience in mentoring and teaching depending on their career goals. The program Director and co-Director will work closely with a Training Oversight Committee and an External Advisory Board. Collaborative relationships with Morehouse School of Medicine and with the University of Massachusetts-Boston (the largest center of higher education for minority students in New England) will help identify ways to recruit underrepresented minorities into the program and to maintain a welcoming environment for these trainees. Additional strategies to measure trainee satisfaction, quantify outcomes, and evaluate the effectiveness of the program will include annual surveys from trainees and mentors, as well as exit and alumni interviews. Institutional support in the form of state-of-art core facilities, technology platforms and funds to support T32-specific training activities and yearly EAB meetings will significantly enhance the training program.